Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Primary listing
Employees
159
Headquarters
Website
SMMT Metrics
BasicAdvanced
$14B
-
-$1.25
-1.14
-
Price and volume
Market cap
$14B
Beta
-1.14
52-week high
$36.91
52-week low
$15.55
Average daily volume
3.9M
Financial strength
Current ratio
3.796
Quick ratio
3.674
Long term debt to equity
1.408
Total debt to equity
2.823
Interest coverage (TTM)
-103,901.44%
Profitability
EBITDA (TTM)
-934.987
Management effectiveness
Return on assets (TTM)
-152.88%
Return on equity (TTM)
-292.49%
Valuation
Price to book
72.25
Price to tangible book (TTM)
73.01
Price to free cash flow (TTM)
-48.422
Free cash flow yield (TTM)
-2.07%
Free cash flow per share (TTM)
-0.385
Growth
Earnings per share change (TTM)
349.52%
3-year earnings per share growth (CAGR)
16.42%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
Bulls say / Bears say
Summit is in active negotiations with AstraZeneca to license its lung cancer candidate, ivonescimab, in a deal potentially worth up to $15 billion, which could deliver substantial upfront and milestone payments (Reuters).
A global study of ivonescimab is set to report data in mid-2025, potentially paving the way for its first U.S. approval and unlocking significant revenue upside upon positive results (Bloomberg).
Ivonescimab has already secured marketing approval in China (May 2024) and is pending a U.S. filing, reflecting accelerated regulatory progress for Summit’s lead oncology candidate (Reuters).
A late-stage study of ivonescimab combined with chemotherapy showed a positive survival trend but failed to achieve statistical significance, raising concerns about its clinical efficacy (Reuters).
Ivonescimab, despite promising early data in China, remains pending U.S. approval and faces competition from established immunotherapies like Keytruda, which could limit its market penetration (Reuters).
Summit reported a net loss of $614.9 million in 2023, underscoring continued cash burn and dependence on external financing to fund operations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos

Why Wall Street Is Backing These 3 Comeback Stocks
MarketBeat2 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Business Wire1 week ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $14B as of October 30, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of October 30, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -1.14. This means that it has an inverse relation to market volatility.